The compliance hub translates regulatory expectations into system design decisions for pharmaceutical digital manufacturing. FDA 21 CFR Part 11, EU GMP Annex 11 and GAMP 5 each describe what a regulated electronic system must do — this hub maps those requirements to concrete architecture, configuration and evidence decisions.
FDA 21 CFR Part 11 for digital systems
21 CFR Part 11 covers electronic records and electronic signatures for FDA-regulated manufacturers. Key requirements include: unique user IDs and passwords, controlled electronic signatures with printed name, date and meaning, closed system audit trails that capture who changed what and when without user override, authority checks, record integrity protection and validation documentation. For pharmaceutical MES, EBR, LIMS and QMS systems in the US or in facilities subject to FDA oversight, Part 11 compliance is not optional. Systems must be designed to enforce these controls, not patched afterward.
EU GMP Annex 11 for computerised systems
Annex 11 covers computerised systems used in GxP pharmaceutical manufacturing and testing in the EU. It requires a risk assessment before validation, supplier assessment, documented validation evidence, user access management, data backup and recovery, security controls, electronic signatures where used, audit trail review as part of release, change control, periodic review and business continuity plans. Annex 11 distinguishes between infrastructure qualification and application validation. It also covers legacy systems, outsourced systems and cloud-hosted services, each with specific evidence requirements.
GAMP 5 validation framework
GAMP 5 provides a risk-based approach to computerised system validation. Systems are classified by software category: Category 1 is infrastructure, Category 3 is non-configurable software, Category 4 is configurable software (most commercial MES, LIMS, QMS), Category 5 is custom software. Validation effort scales with category and risk classification of the intended use. GAMP 5 supports the use of supplier documentation, configuration specifications and critical-thinking tests to reduce scripted testing burden while maintaining objective evidence for regulated functions.
Electronic records and signatures
Systems must protect record authenticity, user accountability, audit trails and controlled approval workflows. Electronic signatures must be linked to their records, non-repudiated and accompanied by the signatories printed name, date, time and meaning of the signature act. Audit trails must capture original and changed values, timestamps, user identity and reason for change. Audit trail review must be part of the batch release process, not a retrospective exercise.
Validation strategy and CSA
GAMP 5 and Computer Software Assurance (CSA) practices help teams scale validation without losing risk-based control. CSA, introduced by FDA, emphasizes critical thinking and objective evidence over documentation volume. It allows teams to leverage supplier testing, reduce scripted testing for low-risk functions and focus validation effort on regulated records, calculations, interfaces and electronic signatures. The goal is the same as traditional CSV: confidence that the system does what it claims and the evidence is available for inspection.
Data integrity operating model
ALCOA+ principles — attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available — define the minimum standard for regulated data quality. Meeting ALCOA+ requires process ownership, access controls, time synchronization, backup and restore procedures, audit trail configuration, deviation review routines and periodic data integrity assessments. Data integrity failures are among the most common findings in FDA warning letters and EU GMP non-compliance reports.
How to use this page
Use this GMP Compliance Hub page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
Evidence to prepare
For GMP Compliance Hub, prepare the records, owners, risks and decision criteria linked to fda 21 cfr part 11 for digital systems, eu gmp annex 11 for computerised systems, gamp 5 validation framework, electronic records and signatures, validation strategy and csa, data integrity operating model. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Frequently asked questions
What is the difference between 21 CFR Part 11 and EU GMP Annex 11?
21 CFR Part 11 is the FDA regulation for electronic records and signatures used in regulated manufacturing and testing. EU GMP Annex 11 is the European standard for computerised systems in GMP environments. Both require validated systems, audit trails, access controls, electronic signatures and data integrity, but they differ in scope and approach. Annex 11 covers the full computerised system lifecycle including supplier assessment, business continuity and periodic review. Part 11 focuses specifically on the electronic record and signature controls. Facilities supplying both US and EU markets must address both.
When should GAMP 5 Category 4 vs Category 5 validation be applied?
GAMP 5 Category 4 covers configurable commercial software such as MES, LIMS, QMS and ERP systems. Validation focuses on configuration specifications, configuration testing and evidence that the configured system performs its GxP functions correctly. Category 5 covers custom software where source code review and more rigorous testing may be needed. Most commercial pharmaceutical software is Category 4. Custom integrations, scripts and bespoke applications that handle regulated data should be assessed as Category 5 unless a strong case exists for lower classification.
What does an ALCOA+ data integrity audit trail review look like?
A thorough audit trail review checks that original values are preserved, changes are attributed to named users with timestamp and reason, there are no unexplained gaps, time synchronization is consistent across systems, and the trail cannot be altered without leaving a traceable record. For batch release, QA should review audit trails for regulated records: batch parameters, electronic signatures, deviations, test results and environmental data. Audit trail review procedures should define review frequency, responsible roles, exception escalation and documentation of the review itself.